Merck KGaA launches Phase 3 push for lupus skin disease with enpatoran trials
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
The agreement could rise to $900 million if key commercial milestones are met
Health innovations are viewed more positively than food and agricultural technologies
Union health minister urges graduates in Chandigarh to combine technological excellence with compassion in medical practice
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The initiative is designed to benefit patients as well as healthcare providers by streamlining access to consultations, diagnostics, and essential care services
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
Subscribe To Our Newsletter & Stay Updated